Loading...
Please wait, while we are loading the content...
Similar Documents
Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
| Content Provider | MDPI |
|---|---|
| Author | Shalata, Walid Jacob, Binil Mathew Agbarya, Abed |
| Copyright Year | 2021 |
| Description | Lung cancer is the most common malignancy across the world. The new era in lung cancer treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both of which have led to improved survival rates. In the present study, we review the changes and development of treatments, with a special focus on adjuvant therapy using tyrosine kinase inhibitors (TKIs) administered to non-small-cell lung carcinoma patients who had a complete resection of the tumor harboring a mutated epidermal growth factor receptor. The clinical trials are dating from the past (chemotherapy trials), present (TKIs), and future (ongoing trials). |
| Starting Page | 4119 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13164119 |
| Journal | Cancers |
| Issue Number | 16 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-08-16 |
| Access Restriction | Open |
| Subject Keyword | Cancers Lung Cancer Adjuvant Treatment Non-small-cell Lung Carcinoma (nsclc) Epidermal Growth Factor Receptor (egfr) Tyrosine Kinase Inhibitor (tki) |
| Content Type | Text |
| Resource Type | Article |
